EUVIMEDObjevte EUVIMED
Open access · CC BY 3.0

The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland

Magdalena Olszewska-Szopa, Anna Czyż, Maria Węgrzyn, Tomasz Wróbel

Advances in Clinical and Experimental Medicine · 2025

DOI: 10.17219/acem/205167 ↗

At a glance

Journal article in Advances in Clinical and Experimental Medicine, 2025. Written by Magdalena Olszewska-Szopa and 3 co-authors. Institution: Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, University Hospital in Wrocław, Wroclaw Medical University, Poland. Major MEDLINE topics: Multiple Myeloma, Dexamethasone, Oligopeptides, Antineoplastic Combined Chemotherapy Protocols. The full text is freely available (open access, CC BY 3.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: The two-drug regimen Kd-70 (carfilzomib at a dose of 70 mg/m2 with dexamethasone) is a recommended treatment option for patients with relapsed or refractory multiple myeloma, according to both American and European guidelines. However, aside from the A.R.R.O.W. trial, real-world data on its effectiveness remain limited. OBJECTIVES: We aimed to assess the effectiveness of the two-drug regimen Kd-70 in real-world practice. MATERIAL AND METHODS: We analyzed data from the Polish Ministry of Health registry, which included 412 patients treated with the Kd-70 regimen in Poland. RESULTS: The overall response rate (ORR) was 67.15%, comparable to the A.R.R.O.W. trial. However, the complete response (CR) rate (5.3%) and very good partial response (VGPR) rate (9.59%) were lower than those reported in the A.R.R.O.W. study. Notably, Kd-70 showed significantly lower efficacy in patients who required treatment for primary resistance or disease progression within the 1st year after diagnosis. In contrast, the number of prior treatment lines did not impact the regimen's effectiveness. CONCLUSIONS: In real-world clinical practice, the Kd-70 regimen demonstrated an ORR comparable to that observed in the A.R.R.O.W. trial. However, the CR and VGPR rates were lower. These findings underscore the need for further investigation into factors influencing treatment outcomes in this patient population.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaDexamethasoneOligopeptidesAntineoplastic Combined Chemotherapy ProtocolsHumansPolandFemaleMaleMiddle AgedAgedAdultTreatment OutcomeRegistriesDrug Administration ScheduleAged, 80 and over

Author keywords

Kd-70carfilzomibmyelomareal-word therapy datarelapsed/refractory myeloma

Substances

DexamethasonecarfilzomibOligopeptides

Authors and institutions

  • Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, University Hospital in Wrocław, Wroclaw Medical University, Poland.
  • Department of Finance, Wroclaw University of Economics and Business, Poland.

Cite

APA

Olszewska-Szopa, M., Czyż, A., Węgrzyn, M., & Wróbel, T. (2025). The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/205167

Vancouver

Olszewska-Szopa M, Czyż A, Węgrzyn M, Wróbel T. The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland. Advances in Clinical and Experimental Medicine. 2025. doi:10.17219/acem/205167

BibTeX
@article{OlszewskaSzopa2025,
  author = {Olszewska-Szopa, Magdalena and Czyż, Anna and Węgrzyn, Maria and Wróbel, Tomasz},
  title = {The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland},
  journal = {Advances in Clinical and Experimental Medicine},
  year = {2025},
  doi = {10.17219/acem/205167}
}
Start for free →